Express 75% of patients maintained complete remission after one year, with positive Phase 2 clinical results of oncolytic virus/PD-1 antibody combination

▎WuXi AppTec Content Team Editor Today, CG Oncology announced that the company's oncolytic virus therapy CG0070, in combination with Merck's anti-PD-1 antibody Keytruda, has been approved in a Phase 2 clinical trial for the treatment of non-muscle invasive bladder cancer.
Positive interim results
.

These patients did not respond to BCG therapy
.

Interim results showed that the combination therapy achieved a complete response rate of 89% in 18 patients who were evaluable for efficacy after 3 months of treatment
.

It is worth mentioning that this innovative therapy has also been approved for clinical use in China, and Lepu Bio has its development rights in China
.

Oncolytic viruses are a class of viruses that can selectively lyse cancer cells.
On the one hand, they can infect tumor cells and cause cell lysis.
On the other hand, the molecules released during the lysis process can also induce innate and adaptive immune responses, attracting more immune cells to continue killing residual tumor cells
.

In addition, many oncolytic viruses can also carry therapeutic transgenes that enhance antitumor efficacy
.

CG0070 is based on an engineered adenovirus type 5 (Ad5) backbone, including a tumor-specific promoter, and a granulocyte-macrophage colony-stimulating factor (GM-CSF) transgene
.

After lysis of tumor cells, GM-CSF is released along with tumor-specific antigens and other danger signals
.

GM-CSF can activate dendritic cells (DCs), which recognize tumor antigens and present them to cytotoxic and helper T cells, thereby promoting their maturation
.

These T cells are then able to circulate throughout the body, recognizing and attacking remaining tumor cells
.

▲The mechanism of action of CG0070 (image source: CG Oncology official website) The latest data released at the AACR conference showed that 85% (n=13) of patients maintained complete remission for more than 6 months, and 78% (n=9) of patients maintained Complete remission over 9 months was 75% (n=8) when assessed after 12 months of treatment
.

"These interim results continue to support the potential of CG0070 to treat BCG-unresponsive bladder cancer patients ," said Mr.
Arthur Kuan, CEO of CG Oncology
.

"As this study nears completion, we look forward to continuing to observe CG0070 in combination with Keytruda.
Positive results
.

" Reference: [1] CG Oncology Presents Interim Phase 2 Data with CG0070 in Combination with KEYTRUDA® (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin.
Retrieved April 13, 2022, from https https:// Disclaimer: The WuXi AppTec content team focuses on introducing global biomedical health research progress
.

This article is for information exchange purposes only, and the views expressed in this article do not represent WuXi AppTec's position, nor do they represent WuXi AppTec's support or opposition to the views expressed in this article
.

This article is also not a treatment plan recommendation
.

For guidance on treatment options, please visit a regular hospital
.